Home > James Ferrara, ASH 2019: Treatment Advances in Patients with GvHD

James Ferrara, ASH 2019: Treatment Advances in Patients with GvHD

Published Online: December 18th 2019

At the 61st ASH Annual Meeting & Exposition, James Ferrara, Icahn School of Medicine at Mount Sinai, discusses his presentation: The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!


1. What are the most important unmet needs in the treatment of patients with graft-versus-host disease (GvHD)? (0:05)

2. What have been the most important recent advances in pretreatment and posttreatment prophylaxis of GvHD? (1:14)

3. What progress has been made in the identification of biomarkers that might predict the risk of GvHD? (2:10)

4. Could you give us a brief overview of the most promising emerging approaches in the treatment of GvHD? (3:08)

5. What factors should be considered when selecting the most appropriate treatment for an individual? (4:32)


James Ferrara is IP for biomarkers of acute GVHD, licensed to VIRACOR

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

Related Videos In Haematology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar